title: Pharmacologic management of chronic reno-cardiac syndrome.
abstract: Chronic kidney disease (CKD) significantly increases cardiovascular morbidity and mortality. CKD remains an under-represented population in cardiovascular clinical trials, and cardiovascular disease is an under-treated entity in CKD. Traditional cardiovascular risk factors in conjunction with uremia-related complications often progress to myocardial dysfunction. Such uremic cardiomyopathy leads to over-activation of neurohormonal pathways with detrimental effects. Management of the reno-cardiac syndrome (RCS) requires the targeting of these multiple facets. In this article we discuss the relevant pathophysiology of RCS, and present the clinical data related to its management.
authors.affiliation: Medicine Institute, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH 44195, USA.
authors.forename: Nael
authors.initials: N
authors.lastname: Hawwa
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Schreiber
authors.forename: W H Wilson
authors.initials: WH
authors.lastname: Tang
mesh_terms: D059347:Cardio-Renal Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D017582:Renal Replacement Therapy / Q000379:methods; D012084:Renin-Angiotensin System / Q000502:physiology; D012307:Risk Factors
chemical_list: D002317:Cardiovascular Agents